Abstract
ABSTRACTHere we report the development of tristearin-based nanostructured-lipid carriers (NLCs) which were further surface-modified with mucoadhesive N,N,N-trimethyl chitosan (TMC) to form mucoadhesive nanostructured-lipid carriers (mNLCs). The NLCs were loaded with high partitioning ropinirole-dextran sulphate (ROPI-DS) nanoplex. NLCs were optimised using Box-Behnken experimental design. Obtaining controlled drug release with prolonged residence on the nasal mucosa for treating Parkinson’s disease (PD) is a major objective of the present investigation. Enhanced brain targetability and improved therapeutic efficacy are the additional objective of this study. Lyophilised NLCs and mNLCs were characterised in solid state by FTIR, DSC, XRD, and HR-TEM analysis. The bioadhesive strength of mNLCs was observed to be 13.3-folds greater compared to NLCs. Plasma and brain pharmacokinetic studies in mice model demonstrated the potential of mNLCs in nose-to-brain drug delivery via olfactory pathway. If investigated for behavioural and neurotoxicity studies clinically, a commercial formulation for patient looks feasible.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
